PDCD1 and hepatocellular carcinoma: Our findings, obtained from a well-annotated cohort of HCC patients, suggest that a simple test based on the PD1+ granulocyte percentage might predict subgroups of patients likely to benefit from atezolizumab–bevacizumab.